Technology
Health
Pharmaceutical
Verrica Pharmaceuticals
$8.959876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$8.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell VRCA and other stocks, options, ETFs, and crypto commission-free!
About
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. Read More The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
CEO
Employees
16
Headquarters
West Chester, Pennsylvania
Founded
2013
Market Cap
230.09M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
60.42K
High Today
$9.00
Low Today
$8.55
Open Price
$9.00
Volume
4.94K
52 Week High
$23.29
52 Week Low
$6.44
Collections
Technology
Health
Pharmaceutical
Medical
Therapy
2018 IPO
US
North America
News
Yahoo FinanceMay 1
Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
WEST CHESTER, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview of the company’s pipeline programs at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2019 at 2:35...
Price Paid on Robinhood
35% Lower
Right Now
52 Week Low
$6.44
Average Price Paid
$13.73
52 Week High
$23.29
Earnings
-$0.30
-$0.28
-$0.27
-$0.25
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours